Cabaletta Bio, Inc. Stock Price, News & Analysis

Cabaletta Bio (Nasdaq: CABA), a biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will speak at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 1:30 p.m. ET. The conference will take place at NASDAQ in New York City.

A live webcast of the event will be available on the company's website, with replays accessible for 30 days. Cabaletta Bio is advancing its CABA™ platform, which includes the CARTA and CAART strategies aimed at developing innovative therapies for various autoimmune conditions. Key product candidates include CABA-201 for lupus nephritis and DSG3-CAART for mucosal pemphigus vulgaris. The company is headquartered in Philadelphia, PA, and is dedicated to providing potentially curative treatments for patients.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, will have its CEO, Steven Nichtberger, M.D., present at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 9:30 a.m. ET. This presentation will be accessible via a live webcast on the company's website, with replays available for 30 days.

The company focuses on developing curative targeted cell therapies for autoimmune diseases, utilizing its CABA™ platform which includes the CARTA and CAART strategies. Key candidates include CABA-201 for lupus nephritis and systemic lupus erythematosus, DSG3-CAART for mucosal pemphigus vulgaris, and MuSK-CAART for MuSK myasthenia gravis. Cabaletta Bio's headquarters are in Philadelphia, PA.

Cabaletta Bio (Nasdaq: CABA) announced the successful clearance of its IND application for CABA-201, a CAR T cell therapy targeting systemic lupus erythematosus (SLE) and lupus nephritis (LN), by the FDA. This milestone was achieved within six months post-licensing, reflecting an efficient clinical trial design informed by prior data. The planned Phase 1/2 trial aims to evaluate the efficacy and safety of CABA-201, with initial results expected by mid-2024. SLE primarily affects young women and poses significant health risks, impacting an estimated 160,000-320,000 patients in the U.S.

Cabaletta Bio (CABA) anticipates Investigational New Drug (IND) clearance for its CABA-201 treatment by mid-2023, with clinical data expected by mid-2024. This fully human CD19-CAR T therapy targets autoimmune diseases and has shown promising preclinical results. The company announced a net revenue of $32.6 million from a public offering in December 2022. R&D expenses rose to $39.3 million for 2022, up from $32.5 million in 2021, while general and administrative costs also increased. Despite these expenses, Cabaletta's cash reserves stood at $106.5 million as of December 31, 2022, ensuring operational funding through Q1 2025.

On February 28, 2023, Cabaletta Bio (Nasdaq: CABA) announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference. This event is set for March 7, 2023, at 2:10 p.m. ET in Boston, MA. A live webcast will be accessible on the company’s website, with replays available for 30 days post-event.

Cabaletta Bio focuses on developing innovative T cell therapies aimed at treating autoimmune diseases. Their CABA™ platform includes the CARTA and CAART strategies, with promising candidates like CABA-201 and DSG3-CAART, which may offer curative solutions for various conditions.

Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will present at the 41^st Annual J.P. Morgan Conference on January 12^th at 7:30 a.m. PT in San Francisco. A live webcast will be available on the company’s website, and replays will be accessible for 30 days. Cabaletta Bio aims to develop potentially curative therapies through its CABA™ platform, which includes lead candidates CABA-201 and DSG3-CAART for conditions like mucosal pemphigus vulgaris.

Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, has announced an underwritten public offering of pre-funded warrants and common stock. The offering aims to sell 6,213,776 pre-funded warrants at $5.51999 each and 126,815 shares of common stock at $5.52, totaling expected gross proceeds of approximately $35 million. The offering, which is oversubscribed and backed by prominent investors, is set to close on December 12, 2022. Proceeds will fund the clinical development of CABA-201 and other ongoing studies.

Cabaletta Bio (Nasdaq: CABA) announced that Dr. Steven Nichtberger will join a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will provide insights into the company's efforts in developing curative targeted cell therapies for autoimmune diseases, including engineered T cell therapies. A live webcast will be accessible on the company's website, with replays available for 30 days afterward. Cabaletta Bio is headquartered in Philadelphia, PA.

Cabaletta Bio, Inc. (Nasdaq: CABA) reported its third-quarter financial results for 2022, highlighting progress in its clinical development of innovative cell therapies for autoimmune diseases. The company plans to submit an IND for CABA-201 in the first half of 2023, with initial data expected by early 2024. Financials show R&D expenses of $8.2 million, unchanged year-over-year, and G&A costs at $3.6 million, up slightly. Cash reserves decreased to $85.9 million from $122.2 million, projecting funds through mid-2024. Regulatory incentives were noted for MuSK-CAART, enhancing future growth prospects.